Chimeric Antigen Receptor T Cell Therapy in Hematology

Ataca P., ARSLAN Ö.

TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.4, pp.285-294, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.4274/tjh.2015.0049
  • Journal Name: TURKISH JOURNAL OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.285-294
  • Keywords: Chimeric antigen receptor T cell, Hematological malignancies, ACUTE MYELOID-LEUKEMIA, ACUTE LYMPHOBLASTIC-LEUKEMIA, ADOPTIVE IMMUNOTHERAPY, ANTITUMOR-ACTIVITY, CANCER REGRESSION, GENE-THERAPY, IN-VIVO, LYMPHOCYTES, TRANSDUCTION, LYMPHOMA
  • Ankara University Affiliated: Yes

Abstract

It is well demonstrated that the immune system can control and eliminate cancer cells. Immune-mediated elimination of tumor cells has been discovered and is the basis of both cancer vaccines and cellular therapies including hematopoietic stem cell transplantation. Adoptive T cell transfer has been improved to be more specific and potent and to cause less off-target toxicity. Currently, there are two forms of engineered T cells being tested in clinical trials: T cell receptor (TCR) and chimeric antigen receptor (CAR) modified T cells. On 1 July 2014, the United States Food and Drug Administration granted 'breakthrough therapy' designation to anti-CD19 CAR T cell therapy. Many studies were conducted to evaluate the benefits of this exciting and potent new treatment modality. This review summarizes the history of adoptive immunotherapy, adoptive immunotherapy using CARS, the CAR manufacturing process, preclinical and clinical studies, and the effectiveness and drawbacks of this strategy.